MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Ofer Gonen will engage in a fireside chat on Wednesday, October 16, 2024, at 9:30 a.m. ET. The discussion will be hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim.

Interested parties can register to attend the virtual fireside chat through the provided link. Additionally, the MediWound management team will be available for one-on-one meetings during the summit. Investors wishing to schedule a meeting are advised to contact their Maxim representative.

YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.

To attend the virtual fireside chat, please register here. In addition, the MediWound management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is FDA and EMA-approved as an orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Building on its proprietary enzymatic platform, MediWound is advancing EscharEx^®, a promising candidate currently in Phase III development for the debridement of chronic wounds. With distinct advantages over the current $360+ million market leader, EscharEx offers a unique opportunity for significant market expansion.

For more information visit www.mediwound.com and follow us on LinkedIn.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008

FAQ

When is MediWound (MDWD) participating in the 2024 Maxim Healthcare Virtual Summit?

MediWound (MDWD) is participating in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024. CEO Ofer Gonen will take part in a fireside chat at 9:30 a.m. ET.

Who will represent MediWound (MDWD) at the 2024 Maxim Healthcare Virtual Summit?

MediWound (MDWD) will be represented by Chief Executive Officer Ofer Gonen at the 2024 Maxim Healthcare Virtual Summit.

How can investors attend MediWound's (MDWD) fireside chat at the Maxim Healthcare Virtual Summit?

Investors can attend MediWound's (MDWD) fireside chat at the Maxim Healthcare Virtual Summit by registering through the link provided in the press release.

Are one-on-one meetings available with MediWound (MDWD) management during the 2024 Maxim Healthcare Virtual Summit?

Yes, one-on-one meetings with MediWound (MDWD) management are available during the 2024 Maxim Healthcare Virtual Summit. Interested investors should contact their Maxim representative to schedule a meeting.